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Abstract
Aims/hypothesis Individuals with type 2 diabetes mellitus
have increased rates of macrovascular disease (MVD). En-
dothelial progenitor cells (EPCs), circulating angiogenic
cells (CACs) and smooth muscle progenitor cells (SMPCs)
are suggested to play a role in the pathogenesis of MVD.
The relationship between vasoregenerative EPCs or CACs
and damaging SMPCs and the development of accelerated
MVD in diabetes is still unknown. We tried to elucidate
whether EPC, CAC and SMPC numbers and differentiation
capacities in vitro differ in patients with and without diabetes
or MVD.
Methods Peripheral blood was obtained from insdividuals
with and without diabetes and MVD (coronary or peripheral
artery disease). EPC and SMPC numbers were determined
with flow cytometry. Furthermore, CAC and SMPC numbers
were quantified after in vitro culture. Their in vitro differenti-
ation capacity was investigated with real-time RT-PCR and
quantitative immunofluorescence.
Results In diabetic patients both EPC and CAC levels were
reduced (1.3-fold [p<0.05] and 1.5-fold [p<0.05], respec-
tively). CAC outgrowth from diabetic patients with MVD
was reduced 1.5-fold compared with diabetic patients with-
out MVD (p<0.05). SMPC levels were similar between
diabetic patients and healthy controls. The CAC/SMPC ratio
of in vitro cultured progenitor cells was reduced 2.3-fold in
samples from diabetic patients (p<0.001). The differentia-
tion capacity of CACs and SMPCs in vitro remained similar
independently of diabetes or MVD.
Conclusions/interpretation The ratio between EPCs or
CACs and SMPCs is disturbed in type 2 diabetes in favour
of SMPCs. This may translate into reduced vascular repair
capacity, thereby promoting MVD in type 2 diabetes.
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CAC Circulating angiogenic cell
CAD Coronary artery disease
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Introduction
Type 2 diabetes mellitus is a complex disease that is asso-
ciated with an increased risk of developing macrovascular
disease (MVD). Patients with diabetes have a two- to four-
fold increased risk of developing coronary artery disease
(CAD) and peripheral artery disease (PAD) compared with
non-diabetic individuals [1]. MVD is mainly the result of
atherosclerosis. The mechanism(s) behind the accelerated
development of atherosclerosis in diabetes is still not fully
understood [2] and cannot be fully explained by the com-
bined effect of established risk factors such as hypertension
and dyslipidaemia.
There is increasing evidence that circulating vascular
progenitor cells play a role in vascular homeostasis and
may contribute to the development of MVD [3]. At least
two types of vascular progenitor cells have been identified:
endothelial progenitor cells (EPCs) and smooth muscle pro-
genitor cells (SMPCs). EPCs contribute to endothelial re-
generation and postnatal neovascularisation [4, 5] by
differentiating into mature endothelial cells and incorporat-
ing into new vessels and/or by secreting pro-angiogenic
growth factors that enhance vascularisation mediated by
resident endothelial cells in a paracrine fashion [6–8]. The
CD34+ population of circulating cells has been shown to
contain EPCs, and a subpopulation of CD34+ cells co-
expressing kinase domain receptor (KDR; also known as
vascular endothelial growth factor receptor 2 [VEGFR-2])
has been shown to be an independent predictor of cardio-
vascular events in patients with CAD [9, 10]. In addition,
cells with vasoregenerative potential can be cultured from
peripheral blood mononuclear cells (PBMCs) using culture
conditions favouring endothelial differentiation [11]. Cells
grown under these conditions were formerly termed ‘early
EPCs’, but are currently referred to as ‘circulating angio-
genic cells’ (CACs). It has been shown that these cells are of
myeloid origin and acquire endothelial-like characteristics
in vitro. While these cells have not been shown to differen-
tiate into mature endothelial cells they can contribute to
vascular repair [12].
It is now well established that several cardiovascular risk
factors, including diabetes, are negatively correlated with
EPC frequency in the circulation [13, 14]. The increased
incidence of atherosclerosis in diabetes has previously been
correlated with a reduction in the number, and changes in
the function of, EPCs [15]. In addition to EPCs it has been
shown that there is also a population of bone-marrow-
derived circulating vascular progenitor cells that have the
capacity to differentiate into smooth muscle cells (SMCs)
[16]. Animal and human studies indicated that these so-
called SMPCs may contribute to the development of athero-
sclerosis by differentiating into mature SMCs or by the
secretion of pro-inflammatory growth factors and cytokines
that promote atherosclerotic plaque growth in a paracrine
fashion [17–19]. A specific subset of circulating monocytes
expressing CD14 and CD105 has been shown to contain
cells with SMPC characteristics. SMPCs can also be obtained
in vitro by culturing PBMCs using selective culture media
[20, 21]. It has previously been shown that patients with CAD
have increased numbers of CD14+CD105+ SMPCs [20]. Fur-
thermore, Nguyen et al showed that SMPC levels were in-
creased in the peripheral blood of patients with type 1 diabetes
[22]. In addition, Westerweel et al observed a disturbed bal-
ance between circulating EPCs/CACs and SMPCs (in fa-
vour of the latter) in patients with end-stage renal disease
(ESRD) who, like diabetic patients, are at increased risk of
developing cardiovascular disease [21].
As yet, it is unknown whether SMPC levels are affected
in type 2 diabetes. Therefore, we test here the hypothesis
that in type 2 diabetes there is an imbalance between the
number of circulating EPCs or CACs and SMPCs that
favours increased differentiation of SMPCs, coinciding with
reduced EPC/CAC-mediated repair capacity. Such a dis-
turbed balance may contribute to increased risk of develop-
ing MVD in patients with diabetes. To this end, we assessed
the number and phenotype of circulating EPCs and SMPCs
using flow cytometry (FACS analysis) in individuals with
and without type 2 diabetes and with or without MVD. To
determine CAC and SMPC differentiation capacity towards
endothelial and smooth muscle cells, respectively, in vitro
cell culture was performed followed by quantification and
differentiation analyses using quantitative immunofluores-
cence and gene expression analysis.
Methods
Individuals Patients with type 2 diabetes and non-diabetic
individuals with and without MVD were recruited and allo-
cated into one of the following six groups: (1) diabetes, no
MVD (n016); (2) diabetes with CAD (n015); (3) diabetes
with PAD (n020); (4) no diabetes, no MVD (i.e. healthy
controls, n019); (5) no diabetes with CAD (n016); and (6)
no diabetes with PAD (n020). Type 2 diabetes mellitus was
diagnosed using blood glucose cut-off values as defined by
WHO. Non-diabetic patients with CAD or PAD were
recruited from the UMCG cardiology and vascular surgery
outpatient clinics, respectively. Diabetes patients with and
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without CAD or PAD were recruited from the UMCG
Diabetes Center. Healthy volunteers were recruited from
the general population. Samples, 50 ml, of peripheral blood
were obtained by venipuncture and collected in EDTA
vacutainers and 10 ml blood was collected in coagula-
tion tubes (BD Biosciences, Franklin Lakes, NJ, USA).
A more detailed description of patient selection criteria
is provided in the electronic supplementary material
(ESM; methods, section 1.1). Written informed consent
was obtained from all study participants. The study
protocol was approved by the local ethics committee
of the University Medical Center Groningen (METc:
2008/335).
Quantification of CPCs by flow cytometry Progenitor cell
frequencies were analysed with FACS in freshly collected
whole blood samples. The total white blood cell (WBC)
count in whole blood samples was determined with a
Poch-100i haematology analyser (Sysmex Nederland,
Etten-Leur, the Netherlands) according to the manufac-
turer’s instructions. EPCs were detected using antibodies
directed against CD34 and KDR. SMPCs were defined by
the dual expression of CD14 and CD105. For more a more
detailed protocol on flow cytometry methods, please refer to
the ESM (methods, section 1.2).
CAC and SMPC culture For CAC and SMPC quantification
and characterisation in vitro, peripheral blood mononuclear
cells were isolated and seeded in fibronectin-coated cham-
ber slides. Pro-angiogenic and profibrotic culture media
were used to obtain outgrowth of CACs and SMPCs, re-
spectively. Details on progenitor cell culture methods are
described in the ESM (methods, section 1.3).
Characterisation of cultured progenitor cells Immunofluor-
escence for differentiation markers for endothelial cells
(ECs; endothelial nitric oxide synthase [eNOS] and KDR)
and SMCs (α-smooth muscle actin [α-SMA] and collagen
type 1) was performed to characterise the differentiation
potential of in vitro cultured CACs and SMPCs. Details on
immunofluorescent staining methods are described in the
ESM (methods, section 1.4).
Quantitative immunofluorescence TissueFAXS analysis Im-
munofluorescent staining of CACs and SMPCs cultured in
vitro were analysed with the TissueFAXS system (Tissue-
gnostics, Vienna, Austria). To quantify the number of
adhering cells in a chamber slide well the number of nuclei
was quantified based on DAPI staining. Subsequently, the
staining intensity of specific antibodies was quantified
based on Cy3 signal intensity. Details on TissueFAXS
analysis methods are described in the ESM (methods,
section 1.5).
Gene expression profile of in vitro cultured CACs and
SMPCs Gene expression analysis was performed using the
Taqman LowDensity Array platform. Details on gene expres-
sion analyses are described in the ESM (methods, section 1.6).
Statistical analysis Data were analysed using Predictive
Analytics SoftWare (PASW, version 18.0.3; IBM, Armonk,
NY, USA) and GraphPad Prism software (version 5; La
Jolla, CA, USA). Data are given as mean±SEM. Dichoto-
mous patient characteristics are expressed as percentages
and compared with the χ2 test. When comparing two groups
the unpaired two-tailed Student’s t test was used. When
comparing three or more groups ANOVA with the Bonfer-
roni post hoc test was used. Differences were considered
significant at p<0.05.
Results
Patient characteristics Patient characteristics are presented
in Table 1. Our aim was to include patients with similar ages
and sex ratios across all groups. While there were no sig-
nificant differences in sex ratios across the groups we found
that diabetic patients with MVD were, on average, slightly
older than the patients from other groups. As anticipated,
diabetic patients had significantly higher HbA1c values com-
pared with non-diabetic individuals (p<0.001). Within the
different subgroups of diabetic patients (with and without
MVD), no differences in glycaemic control were observed.
There was also no significant difference in diabetes duration
between these groups.
Frequency of circulating CD34+ and CD34+KDR+ progenitor
cells is reduced in type 2 diabetes Circulating EPCs were
enumerated using FACS analysis and were identified as
cells with a low side scatter expressing CD34. Within the
CD34+ cells, a subpopulation of CD34+KDR+ cells could be
identified (Fig. 1a). To determine the relative frequency of
EPCs compared with other circulating cells in the peripheral
blood, EPC counts were expressed as the number of cells
per 106 WBCs. The frequency of CD34+ cells was signifi-
cantly reduced (1.3-fold reduction) in diabetic patients com-
pared with healthy controls (Fig. 1b, p<0.05). Within
patients with diabetes there was no difference in CD34+ cell
frequency between diabetic patients with or without MVD
(Fig. 1c). These results suggest that the presence of diabetes
is responsible for the reduction in CD34+ cell levels without
being influenced by the presence of PAD or CAD in these
diabetic patients. This is supported by the observation that in
non-diabetic individuals with MVD (CAD or PAD) the
numbers of CD34+ cells were similar to numbers in healthy
controls (Fig. 1d). In addition to the total CD34+ cell pop-
ulation, the numbers of circulating CD34+KDR+ cells were
Diabetologia (2012) 55:2501–2512 2503
determined. Circulating CD34+KDR+ cell levels were sig-
nificantly reduced (1.7-fold reduction) in diabetic patients
compared with healthy controls (Fig. 1e, p<0.05). Similar to
the total number of CD34+ cells, there was no difference in
Table 1 Patient characteristics




















Age (years) 58.6±2.6 67.6±1.6a 66±1.7b 54.6±1.0 59.6±1.7 57.1±2.4 <0.001
Sex (% male) 7 (44) 11 (55) 7 (47) 11 (58) 15 (75) 11 (69) NS
Body mass index (kg/m2) 32.9±1.6c 31.6±1.9c 31.2±2.0c 25.2±0.7 23.2±0.7 27.0±1.0 <0.001
Type 2 diabetes
duration (years)
17.5±2.2 12.1±1.9 15.1±2.0 NS
Smoking (%) 5 (31) 4 (20) 2 (13) 3 (16) 13 (65)j 9 (56) <0.01
Hypertension (%) 13 (81) 16 (80) 11 (73) 3 (16)j 13 (65) 9 (56) <0.001
Metabolic variables
WBC count (106/ml) 8.1±1.0 8.9±0.7 6,3±0,4 5.9±0.4d 8.2±0.5 6.5±0.6 <0.01
Glucose (mmol/l) 6.4±0.4 8.6±1.0e 8.4±0.8e 5.5±0.2 5.5±0.4 –g <0.01
HbA1c (%) 8.0±0.4
f 7.3±0.3f 7.7±0.3f 5.7±0.1 6.0±0.2 5.7±0.1 <0.001
HbA1c (mmol/mol) 64±5
f 56±3f 61±4f 39±1 42±1.9 39±1 <0.001
Cholesterol (mmol/l) 4.1±0.2 4.2±0.2 4.4±0.3 5.6±0.2i 4.7±0.4 4.4±0.3 <0.01
Triacylglycerol (mmol/l) 1.7±0.2 1.8±0.1 2.5±0.6 1.6±0.2 1.9±0.3 1.8±0.3 NS
HDL-cholesterol (mmol/l) 1.3±0.1 1.5±0.2 1.3±0.2 1.7±0.1 1.3±0.1 1.2±0.1 NS
LDL-cholesterol (mmol/l) 2.3±0.1 2.2±0.2 2.5±0.3 3.4±0.2j 2.7±0.3 2.7±0.2 <0.01
Creatinine (μmol/l) 67.0±4 74.2±5.3 76.4±5.4 77.7±3.7 77.8±5.0 79.7±3.4 NS
Medication
Insulin (%) 14 (88) 10 (50) 12 (80) – – – NS
Oral glucose-lowering
agents (%)
2 (13) 4 (20) 1 (7) – – – NS
Metformin (%) 7 (44) 14 (70) 9 (60) – – – NS
Statins (%) 11 (69) 15 (75) 13 (87) 2 (11)j 16 (80) 16 (100) <0.001
ACE inhibitors (%) 6 (38) 8 (40) 7 (47) 1 (5)j 10 (50) 12 (75)j <0.001
Angiotensin II inhibitor (%) 7 (44)d 4 (20) 3 (20) 0 (0) 3 (15) 2 (13) <0.05
Beta blockers (%) 3 (19) 7 (35) 11 (73)j 1 (5)j 3 (15) 15 (94)j <0.001
Calcium antagonist (%) 5 (31) 6 (30) 8 (53)j 0 (0)j 4 (20) 1 (6) <0.01
Diuretics (%) 9 (56) 7 (35) 8 (53) 1 (5)j 4 (20) 4 (25) <0.05
Antiaggregants (%) 4 (25) 11 (55) 13 (87) 0 (0)j 14 (70) 15 (94)j <0.001
Anticoagulants (%) 1 (6) 4 (20) 0 (0) 0 (0) 2 (10) 1 (6) NS
Data are presented as mean±SEM
Statistically significant with ANOVA compared with:
aType 2 diabetic, non-type 2 diabetic with CAD, non-type 2 diabetic with PAD, and healthy
bNon-type 2 diabetic with CAD, and healthy
cNon-type 2 diabetic with PAD, and healthy
dType 2 diabetic with PAD
eHealthy and non-type 2 diabetic with PAD
fAll non-type 2 diabetic groups
gMeasurement not available
Statistically significant with ANOVA compared with:
hType 2 diabetic, type 2 diabetic with PAD, type 2 diabetic with CAD and non-type 2 diabetic with CAD
iType 2 diabetic, type 2 diabetic with PAD and type 2 diabetic with CAD
jStatistically significant with χ2 test
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the frequency of CD34+KDR+ cells observed between dia-
betic patients with and without MVD (Fig. 1f). In contrast to
the total CD34+ cell population, in non-diabetic patients
with MVD (PAD or CAD), the CD34+KDR+ progenitor cell
subset was reduced to the same extent (1.7-fold reduction)
as observed in diabetes when compared with healthy con-
trols (Fig. 1g; p<0.05).
Frequency of circulating CD14+CD105+ SMPCs is increased
in PAD In addition to EPCs, we also determined the levels
of circulating CD14+CD105+ SMPCs in non-diabetic and
diabetic individuals with and without MVD. As shown in
Fig. 2a, CD14+CD105+ SMPCs represent a small but con-
sistently identifiable subpopulation of CD14+ monocytes.
When comparing healthy control individuals and diabetic
patients (with and without MVD), no significant difference
was observed (Fig. 2b). When subdividing the group of
diabetic patients into individuals with and without MVD
no difference between the two subgroups was observed
(Fig. 2c). These results suggest that in diabetes there is a
selective reduction in EPC levels, whereas SMPC levels are
not significantly affected. However, in contrast to diabetic
individuals, in non-diabetic individuals the number of cir-
culating CD14+CD105+ SMPCs was significantly increased
(2.2-fold) in participants with MVD when compared with
healthy controls (Fig. 2d, p<0.05). When subdividing the
group of non-diabetic patients with MVD into patients with
CAD or PAD, only PAD was associated with significantly
increased SMPC levels (Fig. 2e, p<0.05 and p<0.01 vs
CAD and healthy controls, respectively).
Phenotypic characterisation of cultured CACs and
SMPCs Next we determined CAC and SMPC frequency
in the peripheral blood as well as their respective differen-
tiation capacities towards ECs and SMCs in vitro. HUVECs
and human aortic smooth muscle cells (HASMCs) served as
positive control cells for endothelial- and smooth-muscle-
specific antibodies. HUVECs were positive for KDR and
eNOS but negative for α-SMA and collagen type 1, whereas
HASMCs were positive for α-SMA and collagen type 1 but
did not contain KDR or eNOS (Fig. 3a, b). When PBMCs
were cultured for 7 days under conditions favouring the
outgrowth of CACs, adherent cells showed a small and
rounded morphology. These cells were positive for KDR,
eNOS and collagen type 1, but these in vitro cultured CACs
did not contain α-SMA (Fig. 3c). In contrast, SMPCs
contained α-SMA as well as KDR, eNOS and collagen
type 1 (Fig. 3d), thereby clearly demonstrating phenotypic
overlap of cultured CACs and SMPCs. SMPCs showed an
elongated phenotype resembling HASMCs. We also per-
formed immunofluorescence for the SMC differentiation
markers calponin and smooth muscle myosin heavy chain.
However, we found that both cultured CACs and SMPCs
did not produce these proteins (data not shown). To analyse
the phenotype of in vitro cultured CACs and SMPCs in
Fig. 1 Circulating EPC levels are reduced in type 2 diabetes. (a)
Representative FACS plots and gating profile set on the basis of the
isotype control sample as used for the quantification of CD34+ cells
and CD34+KDR+ cells. (b) CD34+ cell levels were 1.3-fold lower in
type 2 diabetic patients compared with healthy controls. (c) In patients
with type 2 diabetes, similar levels of circulating CD34+ cells were
observed in patients with and without MVD. (d) In non-diabetic
individuals with MVD the total number of CD34+ cells was similar
to that in healthy controls. (e) CD34+KDR+ cell levels were 1.7-fold
lower in type 2 diabetic patients compared with healthy controls. (f) In
type 2 diabetes, similar levels of circulating CD34+KDR+ cells were
observed in patients with and without MVD. (g) In non-diabetic
individuals with MVD the number of CD34+KDR+ cells was signifi-
cantly reduced compared with healthy controls. Data are expressed as
mean values±SEM; *p<0.05. T2DM, type 2 diabetes mellitus
Diabetologia (2012) 55:2501–2512 2505
more detail, real-time RT-PCR was performed for a selected
set of EC and SMC lineage markers using a Taqman Low
Density Array platform. We found that SMPCs derived from
healthy controls expressed significantly higher levels of α-
SMA (also known as ACTA2) and collagen type 1 mRNA
when compared with EPCs from the same individuals. On
the other hand, CACs expressed higher transcript levels of
CD31 (also known as PECAM1) and eNOS (also known as
NOS3; data not shown). In line with our immunofluores-
cence results, we found overlap between the expression of
several EC and SMC marker genes in both CACs and
SMPCs (data not shown).
Quantification of cultured CACs and SMPCs We hypothes-
ised that diabetes and MVD are associated with differences
in CAC and SMPC numbers in addition to an altered dif-
ferentiation potential. To test this hypothesis we first quan-
tified total CAC and SMPC outgrowth potential in vitro by
analysing the number of CACs and SMPCs present after
culture based on nuclear DAPI staining using the Tissue-
FAXS system. To test if the differentiation potential of
CACs and SMPCs is altered by the presence of diabetes
and MVD we next quantified the number of cells positive
for the EC and SMC markers described above, as well as the
staining intensity of these markers as shown in Fig. 3.
Figure 4a,b depicts a representative example of quantitative
analyses of the total number of cultured CACs present from
a healthy individual (Fig. 4a) and a diabetic patient without
MVD (Fig. 4b) within a fixed region in a chamber slide
well. Nuclei present on a total surface area of 29.1 mm2 were
captured and quantitatively analysed using TissueQuest anal-
ysis software. As depicted in Fig. 4a, a sample derived from a
healthy control had a higher CAC count compared with that
from a diabetic patient without MVD. Quantitative analysis
revealed that CAC outgrowth (expressed as cells per mm2)
was significantly reduced (1.5-fold reduction) in diabetic
patients (with or without MVD) compared with healthy con-
trols (Fig. 4c, p<0.05). When dividing diabetic individuals
into patients with and without MVD, significantly reduced
(1.5-fold reduction) CAC outgrowth was observed in diabetic
patients with MVD compared with patients without MVD
(Fig. 4d, p<0.05). When we expressed the number of CACs
per 106WBCs we also found a reduction in CAC frequency in
diabetic patients with MVD compared with diabetic patients
Fig. 2 SMPC levels are increased in patients with MVD but without
type 2 diabetes. (a) SMPCs were identified within a monocyte gate
based on forward and side scatter characteristics. Within the monocyte
gate, CD14+ cells expressing CD105 were quantified based on the
isotype (IgG1) control. (b) SMPC levels were similar between type 2
diabetic patients and healthy controls. cWithin type 2 diabetic patients
there were no differences in the SMPC frequencies between patients
with and without MVD. (d) Within non-diabetic patients, individuals
with MVD had 2.2-fold higher circulating SMPC levels compared with
healthy controls. (e) Only the presence of PAD was associated with
increased numbers of SMPCs compared with healthy controls (p<
0.01) and CAD (p<0.05). Data are expressed as mean values±SEM;
*p<0.05 and **p<0.01 T2DM, type 2 diabetes mellitus
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without MVD (ESM Table 1). This MVD-associated addi-
tional reduction in CAC outgrowth was not observed in non-
diabetic individuals with MVD (Fig. 4e).
Quantification of SMPC outgrowth after in vitro culture
was performed in a similar manner to that for cultured CACs
as described above. Figure 5a,b depicts a representative
example of quantitative analyses of the total number of
cultured SMPCs from a healthy individual present within a
fixed region in a chamber slide well (left two panels) and
from a non-diabetic patient with PAD (right two panels). In
line with our CD14+CD105+ FACS data (Fig. 2b) we did not
find a significant difference in SMPC numbers after in vitro
culture (expressed as cells per mm2) in diabetic patients
when compared with healthy controls (Fig. 5c). However,
when we expressed the number of SMPCs per 106 WBCs or
as number of cells per ml blood we did find significantly
increased SMPC numbers in diabetic patients compared
with healthy controls (ESM Table 1). No difference in
SMPC outgrowth was observed between diabetic patients
with and without MVD (Fig. 5d). However, in non-diabetic
individuals a significantly higher number (1.8-fold increase)
of outgrowth SMPCs were observed in patients with MVD
compared with healthy controls (Fig. 5e, p<0.05). When
stratifying non-diabetic patients with MVD into patients
with either PAD or CAD we observed that only the presence
of PAD, but not CAD, was associated with significantly
increased (twofold) SMPC outgrowth when compared with
healthy controls (Fig. 5f, p<0.05).
Differentiation of cultured CACs and SMPCs To assess
whether the differentiation potential of outgrowth CACs
towards an EC phenotype was altered in diabetes and
MVD we determined the percentage of CACs positive for
KDR or eNOS staining using TissueFAXS analysis.
Figure 4f,g shows a representative example of the gating
strategy performed using TissueQuest analysis software.
The proportion of CACs producing KDR was similar
among all groups. However, the percentage of CACs pro-
ducing eNOS was significantly increased in diabetic patients
(with or without MVD, Fig. 4h, p<0.05) and non-diabetic
patients with MVD (Fig. 4j, p<0.001) compared with
healthy controls. The percentage of eNOS+ CACs was sim-
ilar between diabetic patients with and without MVD
(Fig. 4i). Next, we compared the mean fluorescence inten-
sity ratio of the eNOS staining to investigate if the average
level of eNOS per cell was affected by diabetes or MVD.
Despite the higher percentage of CACs producing eNOS in
diabetic and non-diabetic patients with MVD, the eNOS
Fig. 3 The phenotype of in vitro cultured HUVECs, HASMCs, CACs
and SMPCs. Pictures were taken at×200 and×630 (inset) magnifica-
tion. (a) HUVECs and (b) HASMCs were used as positive controls for
the assessment of expression of EC and SMC differentiation markers.
(c) CACs contained collagen type 1, KDR and eNOS, but not α-SMA.
(d) SMPCs contained α-SMA, collagen type 1, KDR and eNOS.
Nuclear staining is shown in blue (DAPI) while positive staining with
the respective antibodies is shown in red. Col1, collagen type 1. BF,
Bright field
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staining intensity was similar among the groups (not
shown). In addition, the absolute number of eNOS+ CACs
per mm2 was not altered (not shown). Real-time RT-PCR
showed that there was no difference in mRNA expression of
EC differentiation markers among the groups (ESM Table 2).
Taken together, the results from the TissueFAXS quantifica-
tion and the differentiation analyses show that diabetes and
MVD are associated with a reduction in the number of cul-
tured CACs, but the differentiation capacity of these cells is
unaltered.
As for CACs, we assessed whether diabetes or MVD
affected the differentiation potential of outgrowth SMPCs.
To this end we quantified the percentage of SMPCs con-
taining α-SMA with immunofluorescence. A representative
Fig. 4 CAC outgrowth in culture is reduced in type 2 diabetic patients.
(a,b) Representative images and corresponding scatterplots of DAPI-
stained CAC nuclei, which were quantified with the TissueFAXS
system. The scatterplots show the total number of nuclei that were
quantified in a fixed region in a representative healthy control (a) and a
type 2 diabetic patient without MVD (b). (c) CAC outgrowth was
reduced 1.5-fold in type 2 diabetic patients compared with healthy
controls. (d) Within type 2 diabetic individuals, patients with MVD
displayed a 1.5-fold reduction in the number of outgrowth CACs
compared with type 2 diabetic patients without MVD. (e) Within
non-type 2 diabetic individuals, similar CAC levels were observed in
individuals with and without MVD. (f,g) The presence of eNOS was
assessed using TissueFAXS analysis: (f) negative control staining; and
(g) eNOS staining. (h) The percentage of CACs containing eNOS was
increased in type 2 diabetic patients compared with healthy controls
(h), but not according to MVD status in type 2 diabetic patients (i). (j)
Individuals with MVD but not type 2 diabetes had significantly higher
frequencies of CACs containing eNOS compared with healthy controls.
Data are expressed as mean values±SEM; *p<0.05, ***p<0.001.
T2DM, type 2 diabetes mellitus
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example of the gating strategy performed using TissueQuest
analysis software is shown in Fig. 5g,h. Although the per-
centages of α-SMA+ outgrowth SMPCs tended to be higher
in diabetic patients with and without MVD (vs healthy
controls, Fig. 5i), in diabetic patients with MVD (vs diabetes
without MVD, Fig. 5j), and in non-diabetic patients with
MVD (vs healthy controls, Fig. 5k), no significant differ-
ences were observed because of relatively large variations
within the groups. Gene expression data obtained with real-
time RT-PCR showed that several genes were differentially
Fig. 5 SMPC outgrowth is increased in non-type 2 diabetic patients
with PAD. (a,b) Representative images and corresponding scatterplots
of DAPI-stained SMPC nuclei quantified with the TissueFAXS system.
The scatterplots show the total number of nuclei that were quantified in
a fixed region in a representative healthy control (a) and a non-type 2
diabetic patient with PAD (b). (c) There was no significant difference
in SMPC numbers between type 2 diabetic patients and healthy con-
trols. (d) Within type 2 diabetic patients, similar SMPC numbers were
detected in patients with and without MVD. (e) Within non-diabetic
individuals, patients with MVD had a 1.8-fold increase in the number
of outgrowth SMPCs compared with healthy controls. (f) Within non-
diabetic patients, SMPC levels were increased 2.0-fold in PAD patients
compared with healthy controls. (g,h) The presence of α-SMA was
assessed using TissueFAXS analysis: (g) negative control staining; and
(h) α-SMA staining. There was a tendency towards increased percen-
tages of α-SMA+ outgrowth SMPCs in: (i) type 2 diabetic patients with
and without MVD compared with healthy controls; (j) type 2 diabetic
patients with MVD, compared with those without MVD; and (k) non-
type 2 diabetic patients with MVD compared with healthy controls.
Data are expressed as mean values±SEM; *p<0.05. T2DM, type 2
diabetes mellitus
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expressed in SMPCs when comparing all groups (ESM
Table 3). However, we did not observe an association of
differential expression of a complete panel of EC or SMC
marker genes with diabetes or MVD, indicating that the
differentiation potential of SMPCs is not altered by either
of these diseases.
Type 2 diabetes is associated with reduced CAC/SMPC and
EPC/SMPC ratios To determine if the balance between
CACs and SMPCs was disturbed by the presence of diabetes
and/or MVD, the CAC/SMPC ratio was calculated based on
the in vitro data shown in Figs 4 and 5. Compared with
healthy controls, the CAC/SMPC ratio is significantly re-
duced (2.3-fold reduction) in diabetes (Fig. 6a, p<0.001). In
non-diabetic individuals, the presence of MVD was associ-
ated with a 2.9-fold reduction in the CAC/SMPC ratio
(Fig. 6b, p<0.001). As diabetes without MVD was already
associated with a markedly reduced CAC/SMPC ratio, no
additional reduction was observed in diabetes with MVD
(Fig. 6c). When we calculated the EPC/SMPC ratio based
on the data obtained with FACS we found a significantly
reduced CD34+ cell/CD14+CD105+ SMPC ratio (2.7-fold
reduction, p<0.01) and CD34+KDR+ cell/CD14+CD105+
SMPC ratio (3.7-fold reduction, p<0.01) in diabetic patients
compared with healthy controls. There was no additional
reduction of these ratios associated with MVD in diabetic or
non-diabetic individuals (data not shown). Together these
data indicate that the presence of type 2 diabetes is associ-
ated with a significant decrease in the CAC/SMPC and
EPC/SMPC ratios.
Discussion
The main finding of this study is that the numerical balance
between circulating progenitor cells with vasoregenerative
capacity (EPCs and CACs) and damaging SMPCs is altered
in favour of SMPCs in type 2 diabetes. Using established
FACS protocols for the detection of EPCs and SMPCs we
observed that the frequency of circulating CD34+ and
CD34+KDR+ cells is reduced in patients with diabetes,
whereas the levels of CD14+CD105+ SMPCs are not signif-
icantly changed by the presence of diabetes. We additionally
investigated CAC and SMPC frequency and phenotype
using in vitro cell culture of patient-derived PBMCs under
pro-angiogenic or pro-fibrotic conditions. Under these con-
ditions a subset of adherent PBMCs differentiated towards
CACs or SMPCs, respectively. Similar to the results
obtained with FACS for EPCs, we found a significant re-
duction in CAC outgrowth in vitro when culturing PBMCs
derived from diabetes patients. The presence of MVD (ei-
ther CAD or PAD) in diabetes was associated with an
additional decrease in CACs. This MVD-associated reduc-
tion in CAC levels in vitro was not observed in our FACS
analysis of EPCs. A likely explanation for this discrepancy
is that cultured CACs represent a subtype of vasoregener-
ative cells that is different from the bone-marrow-derived
EPCs originally described by Asahara et al [4]. These
different cell types may be differentially affected by MVD.
It has been shown that CACs cultured in vitro are derived
from a subset of CD14+ monocytes rather than CD34+ bone
marrow-derived progenitor cells as identified by FACS [23].
SMPC outgrowth potential in vitro was not significantly
affected by diabetes. This suggests that diabetes predomi-
nantly causes a decrease in the number of EPCs and CACs
rather than an increase in SMPCs.
Diabetes is shown to cause defective progenitor cell
mobilisation from the bone marrow in response to ischaemia
[24]. However, it seems that this is limited to EPCs and
CACs as we show that SMPC levels remain the same or are
even slightly elevated in diabetic patients, regardless of the
presence of MVD. These results contrast with the data
Fig. 6 The CAC/SMPC ratio (cells per mm2) is decreased in type 2
diabetic patients and individuals with MVD. (a) The CAC/SMPC ratio
shows a 2.3-fold decrease in type 2 diabetic patients compared with
healthy controls. (b) Within non-diabetic individuals, the CAC/SMPC
ratio was decreased 2.9-fold in patients with MVD compared with
healthy controls. (c) Within patients with type 2 diabetes there was
no difference in the CAC/SMPC ratio between patients with or without
MVD. Data are expressed as mean values±SEM; ***p<0.001. T2DM,
type 2 diabetes mellitus
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reported by Nguyen et al showing significantly increased
SMPC levels (referred to as myofibroblast progenitor cells
[MFPCs] in their study) in type 1 diabetes patients that
could possibly influence MVD rates in these patients [22].
These contrasting observations cannot be explained by dif-
ferences in glycaemic control between the study populations
because in both studies participants were relatively well
controlled as judged by HbA1c levels. Our results are in
agreement with a study performed by Westerweel et al who
found reduced EPC numbers with preserved SMPC levels in
patients with ESRD compared with healthy controls [21].
As for diabetic patients, individuals with ESRD are at in-
creased cardiovascular risk including MVD, underscoring
the association of disturbed EPC/SMPC and CAC/SMPC
balances with adverse vascular remodelling.
The ratio between EPC or CAC numbers and SMPC
numbers was significantly lower for individuals with diabe-
tes compared with healthy controls. This reduced ratio was
independent of the presence of MVD, suggesting also that
diabetic patients without MVD are at increased risk of
developing MVD, despite not having the clinical symptoms
at the time of analysis.
In contrast to diabetic individuals with MVD, the pres-
ence of MVD in non-diabetic patients was associated with
significantly increased SMPC levels. This increase was con-
fined to non-diabetic patients with PAD, as demonstrated
with both FACS analysis and in vitro cell culture. Increased
SMPC levels were not found in non-diabetic patients with
CAD despite similar baseline characteristics and metabolic
variables. Our data therefore suggest that the imbalance in
EPC/CAC and SMPC levels is more relevant for the devel-
opment of PAD than CAD in non-diabetic patients. The
mechanism behind this observation remains to be identified.
In addition to numerical changes in EPC, CAC and
SMPC frequency in diabetic patients, we also investigated
the differentiation capacities of CACs and SMPCs in vitro.
An altered differentiation capacity of progenitor cells might
contribute to increased rates of atherosclerosis in diabetic
patients. Increased differentiation of progenitor cells to-
wards SMCs could promote plaque growth by increasing
the volume of the fibrous cap. On the other hand, reduced
differentiation of CACs towards mature ECs could inhibit
arteriogenesis and angiogenesis, which could worsen is-
chaemia downstream of the plaque. However, using EC-
and SMC-lineage-specific immunofluorescence and gene
expression analysis we found that the phenotype of out-
growth CACs and SMPCs in vitro was similar among the
groups. Therefore, numerical changes rather than an altered
differentiation capacity of CACs and SMPCs may contribute
to the development of MVD.
In conclusion, our study demonstrates a disturbed bal-
ance between circulating EPCs or CACs and SMPCs in type
2 diabetes in favour of a numerical decrease in EPCs and
CACs, resulting in a relative increase in SMPC numbers.
This imbalance may contribute to a decreased capacity for
vascular repair in type 2 diabetic patients, increasing their
risk of developing MVD.
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